Cargando…

Involvement of multidrug resistance protein 4 in the hepatocyte efflux of lamivudine and entecavir

Multidrug resistance protein 4 (MRP4) is capable of transporting acyclic nucleotide phosphonates, but little is known about its role in lamivudine (LAM) and entecavir (ETV) transport. In the present study, the involvement of MRP4 in the transport of LAM and ETV was investigated through in vitro expe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yu-Tian, Liu, Wei, Zhu, Gang-Yan, Wang, Fu-Liang, Chen, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928661/ https://www.ncbi.nlm.nih.gov/pubmed/29568871 http://dx.doi.org/10.3892/mmr.2018.8779

Ejemplares similares

Entecavir and lamivudine therapy for severe acute chronic hepatitis B
por: LIU, CHANGHONG, et al.
Publicado: (2013)

De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine
por: Yang, Song, et al.
Publicado: (2016)

Efficacy of Lamivudine or Entecavir on Acute Exacerbation of Chronic Hepatitis B
por: Kanda, Tatsuo, et al.
Publicado: (2011)

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
por: Sheng, Yun-Jian, et al.
Publicado: (2011)

Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
por: Wang, Guiliang, et al.
Publicado: (2015)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
por: Jeon, Hee-Jeong, et al.
Publicado: (2017)

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
por: Kim, Hong Joo, et al.
Publicado: (2016)

Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis
por: Henriquez-Camacho, Cesar, et al.
Publicado: (2023)

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
por: Hwang, Joo An, et al.
Publicado: (2015)

Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: A pilot study
por: Du, Qing-Wei, et al.
Publicado: (2013)

Comparative Effectiveness of Lamivudine versus Entecavir in Patients with Hepatocellular Carcinoma: Watch out for Confounders!
por: Kim, Hwi Young
Publicado: (2016)

Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma
por: Kim, Jung Hee, et al.
Publicado: (2016)

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine
por: Yasutake, Yoshiaki, et al.
Publicado: (2020)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
por: Ze, EunYoung, et al.
Publicado: (2014)

The role of lamivudine versus entecavir in prevention of HCC in patients with hepatitis B virus-related cirrhosis
por: Olariu, Cristina, et al.
Publicado: (2013)

Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir
por: Jayakumar, Rajeswari, et al.
Publicado: (2012)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

Role of Novel Multidrug Efflux Pump Involved in Drug Resistance in Klebsiella pneumoniae
por: Srinivasan, Vijaya Bharathi, et al.
Publicado: (2014)

Entecavir Versus Lamivudine Therapy for Patients With Chronic Hepatitis B-Associated Liver Failure: A Meta-Analysis
por: Zhang, Xiaoguo, et al.
Publicado: (2014)

Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety
por: Lian, Jiang-Shan, et al.
Publicado: (2019)

Evaluation of the Cost-Effectiveness of Entecavir Versus Lamivudine in Hepatitis BeAg-Positive Chronic Hepatitis B Patients
por: Yuan, Yong, et al.
Publicado: (2008)

Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10)
por: DENG, WEN, et al.
Publicado: (2013)

The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis
por: Yang, Jiao, et al.
Publicado: (2016)

Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology
por: Xue, Xue, et al.
Publicado: (2012)

Efficacy of Lamivudine or Entecavir against Virological Rebound after Achieving HBV DNA Negativity in Chronic Hepatitis B Patients
por: Miyauchi, Tomoo, et al.
Publicado: (2013)

Comparison of patients using lamivudine, entecavir, and tenofovir according to liver fibrosis markers fibrosis-4 and aspartate aminotransferase-to-platelet ratio index scores
por: Okan, Huseyin Dogus, et al.
Publicado: (2023)

Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model
por: Zhang, Jingmin, et al.
Publicado: (2018)

Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis
por: Liu, Fen, et al.
Publicado: (2014)

Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B
por: WANG, YANG, et al.
Publicado: (2016)

A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy
por: Chen, Wen-Chi, et al.
Publicado: (2015)

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)

Molecular Diagnosis of Entecavir Resistance
por: Sayan, Murat
Publicado: (2010)

Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates
por: Koenderink, Jan B., et al.
Publicado: (2020)

Adherence to Medication Is a More Important Contributor to Viral Breakthrough in Chronic Hepatitis B Patients Treated with Entecavir Than in Those with Lamivudine
por: Kamezaki, Hidehiro, et al.
Publicado: (2013)

A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B
por: Lee, Kyung Jae, et al.
Publicado: (2018)

Efflux-mediated fluoroquinolone resistance in the multidrug-resistant Pseudomonas aeruginosa clinical isolate PA7: identification of a novel MexS variant involved in upregulation of the mexEF-oprN multidrug efflux operon
por: Morita, Yuji, et al.
Publicado: (2015)

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China
por: Gu, Lijun, et al.
Publicado: (2015)

Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosis
por: Machado, Diana, et al.
Publicado: (2012)

Impact of efflux in the development of multidrug resistance phenotypes in Staphylococcus aureus
por: Costa, Sofia Santos, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_abhqpu49h2g5sbrup68ok36g35